[Oradlist] mail survey

[Johan Aps]

Dear Friends,

A couple of weeks ago a similar issue came up on OradList.
I promptly posted a case report I wrote, but apparantly the OradList  
editor did not allow it onto the list.
In the case report is a protocol that can be followed in case of  
bisphosphonates.

So maybe the OradList editor can "resend" the abstract (PDF file) I  
send before.

Hoping to be of any help and very keen to know how other centres deal  
with bisphosphonates,

Kind regards from a sunny Belgium,

Johan
-- 
Prof. dr. Johan Aps (DDS- Cert. Paed. Dent. & Special Care - MSc DMFR - PhD)
Head of Medical Imaging in Dentistry
Senior Clinical Consultant
Dental School & Ghent University Hospital
Ghent University
UZG-P8- Dental School- De Pintelaan 185, 9000 Gent - Belgium
(tel)+32 9 332 51 02
johan.aps at ugent.be



Citeren Lennart Flygare <Lennart.Flygare at nll.se>:

> Dear Allan.
>
> Very interesting!
> Can you please supply me with references to some of the scientific   
> studies you refer to below?
>
> Best wishes
>
> Lennart F
>
>
> -------------------------------------
> Lennart Flygare, Odont Dr
> Senior Consultant
> Dentomaxillofacial Radiology
> Dept of Radiology
> Sunderby Hospital
> SE-971 80 Luleå
> SWEDEN
>
> tel+46-920-282931
> mob: +46-70-6743858
> fax:+46-920-282942
> -----Ursprungligt meddelande-----
> Från: oradlist-bounces at lists.ucla.edu   
> [mailto:oradlist-bounces at lists.ucla.edu] För Allan G Farman
> Skickat: den 2 maj 2009 08:34
> Till: oradlist at lists.ucla.edu
> Ämne: Re: [Oradlist] mail survey
>
> Scientific studies have indicated that low doses of orally   
> administered bisphosphonates are unlikely to be associated with   
> untoward effects, and that the majority of cases of "bisphosphonate"  
>  osteonecrosis tend to be in folk receiving high doses as part of th  
>  regimen of chemotherapy for cancer. However osteonecrosis can occur  
>  in the absence of any bisphosphonate history so it obviously can   
> occur on rare occasion in folk who take low doses for osteoporosis   
> prevention just as a coincidence. Such incidences can then be   
> misinterpreted unscientifically as "proof that the scientists have   
> it all wrong."
>
> In the presence of controversy what is a practitioner to do? Often   
> the safe bet is not to be involved in a situation that can lead to   
> prosecution for malpractice even when the scientific evidence is on   
> your side... so dentists might not follow guidelines issued by the   
> American Dental Association and simply refuse to treat or refer such  
>  patients.
>
> I am unaware of any national surveys that have assessed the   
> knowledge of US dentists on the topic of bisphosphonates, or   
> measured the present trends in treatment.
>
> AGF
>
>
> Allan G. Farman, BDS, PhD, MBA, DSc, Diplomate ABOMR
>
> Prof. Radiology & Imaging Science
> Univ. Louisville School of Dentistry: SUHD
> 501 South Preston Street,
> Louisville, Kentucky 40292, USA
>
> Tel: +1(502) 852.1241
> Fax: +1(502)852.1626
>
>
>>>> Akira Taguchi <akiratag at nifty.com> 05/01/2009 10:03 PM >>>
> Dear oradlist members,
>
> Please let me know how the dentists in your country deal with the
> patients who receive the bisphosphonate (BS) for osteoporosis
> treatments.
> Recently, there are some rumor damage about this issue in Japan.
> I mean many Japanese dentists tend to refuse dental treatment in
> patients who receive BS for osteoporosis treatment.
> How about your country?
> It is very important for me (or for us) to know the trend worldwide
> because triaging screening for osteoporosis in dental clinics may not
> be meaningful if this trend is common over the world.
>
> Thank you so much in advance.
>
> Best wishes,
>
> Akira Taguchi
>
> ////////////////////////////////////////////////////////////////////////////////
> Akira Taguchi, DDS, PhD
> Chair and Professor
> Department of Oral and Maxillofacial Radiology
> School of Dentistry
> Professor
> Department of Hard Tissue Research
> Graduate School of Oral Medicine
> Matsumoto Dental University
> 1780 Gobara, Hirooka, Shiojiri 399-0781 JAPAN
> TEL: 81263512095
> FAX: 81263512096
> E-mail: akiratag at nifty.com
>               akiro at po.mdu.ac.jp
> ////////////////////////////////////////////////////////////////////////////////
>
>
>
>
>
>
>
>
>
>
>
>
>
> _______________________________________________
> Oradlist mailing list
> Oradlist at lists.ucla.edu
> http://lists.ucla.edu/cgi-bin/mailman/listinfo/oradlist
>
>
>
> _______________________________________________
> Oradlist mailing list
> Oradlist at lists.ucla.edu
> http://lists.ucla.edu/cgi-bin/mailman/listinfo/oradlist
> _______________________________________________
> Oradlist mailing list
> Oradlist at lists.ucla.edu
> http://lists.ucla.edu/cgi-bin/mailman/listinfo/oradlist
>